In vivo evaluation of CYP1A2, CYP2A6, Nat-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios

Biomedical Chromatography

Volumn 21, Issue 2, 2007, Pages 190-200

  Begas, E ^a   Kouvaras, E ^a   Tsakalof, A ^a   Papakosta, S ^a   Asprodini, E K ^a  

^a UNIVERSITY OF THESSALY   (Greece)

Author keywords

Caffeine; CYP1A2; CYP2A6; HPLC; NAT 2; XO

Indexed keywords

ACETIC ACID; BIOMOLECULES; BODY FLUIDS; CAFFEINE; CHLORINE COMPOUNDS; ENZYME ACTIVITY; METABOLISM; METHANOL; ORGANIC SOLVENTS; PH;

ACETYL TRANSFERASE; CYP1A2; CYP2A6; HPLC; IN-VIVO; N ACETYLS; N-ACETYL-TRANSFERASE-2; RP-HPLC METHOD; VIVO EVALUATION; XANTHINE OXIDASE;

METABOLITES;

1 METHYLURIC ACID; 1 METHYLXANTHINE; 1,7 DIMETHYLURIC ACID; 2 PROPANOL; 5 ACETAMIDO 6 FORMYLAMINO 3 METHYLURACIL; ACETIC ACID; ACETONITRILE; ARYLAMINE ACETYLTRANSFERASE; CAFFEINE; CHLOROFORM; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; METHANOL; METHYLXANTHINE; PARAXANTHINE; SOLVENT; XANTHINE OXIDASE;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; FOOD INTAKE; GREECE; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; MALE; METABOLITE; MONITORING; NORMAL HUMAN; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SMOKING; URINALYSIS; URINE LEVEL; VOLUNTEER;

EID: 33847079175     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.736     Document Type: Article

References (58)

1. Aklillu E, Carrillo JA, Makonnen E, Bertilsson L and Ingelman-Sundberg M. Xanthine oxidase activity is influenced by environmental factors in Ethiopians. European Journal of Clinical Pharmacology 2003; 59: 533-536.
2. Ambrose DL and Fritz JS. High-performance liquid chromatographic determination of drugs and metabolites in human serum and urine using direct injection and a unique molecular sieve. Journal of Chromatography B Biomedical Sciences and Applications 1998; 709: 89-96.
3. Aoyama T, Yamano S, Guzelian PS, Gelboin HV and Gonzalez FJ. Five of 12 forms of vaccinia virus-expressed human hepatic cytochrome P450 metabolically activate aflatoxin B1. Proceedings of the National Academy of Sciences, USA 1990; 87: 4790-4793.
4. Asprodini EK, Zifa E, Papageorgiou I and Benakis A. Determination of N-acetylation phenotyping using caffeine as a metabolic probe. European Journal of Drug Metabolism and Pharmacokinetics 1998; 23: 501-506.
5. Baud-Camus F, Marquet P, Soursac M, Davrinche C and Farinotti R. Determination of N-acetylation phenotype using caffeine as a metabolic probe and high-performance liquid chromatography with either ultraviolet detection or electrospray mass spectrometry. Journal of Chromatography B Biomedical Sciences and Applications 2001; 760: 55-63.
6. Bechtel YC, Haffen E, Lelouet H, Brientini MP, Paintaud G, Miguet JP and Bechtel PR. Relationship between the severity of alcoholic liver cirrhosis and the metabolism of caffeine in 226 patients. International Journal of Clinical Pharmacology and Therapeutics 2000; 38: 467-475.
7. Bendriss E, Markoglou N and Wainer IW. Liquid chromatographic method for the simultaneous determination of caffeine and fourteen caffeine metabolites in urine. Journal of Chromatography B Biomedical Sciences and Applications 2000; 746: 331-338.
8. Bertilsson L, Carrillo JA, Dahl ML, Llerena A, Alm C, Bondesson U, Lindstrom L, Rodriguez de la Rubia I, Ramos S and Benitez J. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. British Journal of Clinical Pharmacology 1994; 38: 471-473.
9. Bonati M, Latini R, Galleti F, Young JF, Tognoni G and Garattini S. Caffeine disposition after oral doses. Clinical Pharmacological and Therapeutics 1982; 32: 98-106.
10. Butler MA, Iwasaki M, Guenglerich FP and Kadlubar FF. Human cytochrome P-450Pa (P-4501A2), the phenacetin O-de-ethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proceedings of the National Academy of Sciences, USA 1989; 86: 7696-7700.
11. Campbell ME, Grant DM, Inaba T and Kalow W. Biotransformation of caffeine, paraxantine, theophylline and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes. Drug Metabolism and Disposition 1987a; 15: 237-249.
12. Campbell ME, Spielberg SP and Kalow W. A urinary metabolite ratio that reflects systemic caffeine clearance. Clinical Pharmacology and Therapeutics 1987b; 42: 157-165.
13. Camus AM, Geneste O, Honkakoski P, Bereziat JC, Henderson CJ, Wolf CR, Bartsch H and Lang MA. High variability of nitrosamine metabolism among individuals: role of cytochromes P450 2A6 and 2E1 in the dealkylation of N-nitrosadimethylamine and N-nitrosodiethylamine in mice and humans. Molecular Carcinogenesis 1993; 7: 268-275.
14. Carrillo JA and Benitez J. Caffeine metabolism in a healthy Spanish population: N-Acetylator phenotype and oxidation pathways. Clinical Pharmacology and Therapeutics 1994; 55: 293-304.
15. Carrilio JA, Christensen M, Ramos SI, Alm C, Dahl M-L, Benitez J and Bertilsson L. Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva and urine. Therapeutic Drug Monitoring 2000; 22: 409-417.
16. Cascorbi I, Drakoulis N, Brockmoller J, Maurer A, Sperling K and Roots I. Arylamine N-acetyltranferase (NAT-2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. American Journal of Human Genetics 1995; 57: 581-592.
17. Castorena-Torres F, Mendoza-Cantu A, de Leon MB, Cisneros B, Zapata-Perez O, Lopez-Carrillo L, Salinas JE and Albores A. CYP1A2 phenotype and genotype in a population from the Carboniferous Region of Coahuila, Mexico. Toxicology Letters 2005; 156: 331-339.
18. Caubet M-S, Elbast W, Dubuc M-C and Brazier J-L. Analysis of urinary caffeine metabolites by HPLC-DAD: the use of metabolic ratios to assess CYP1A2 enzyme activity. Journal of Pharmaceutical and Biomedical Analysis 2002; 27: 261-270.
19. Denaro CP, Wilson M, Jacob P 3rd and Benowitz NL. The effect of liver disease on urine caffeine metabolite ratios. Clinical Pharmacology and Therapeutics 1996; 59: 624-635.
20. Dobrocky P, Bennett PN and Notarianni LJ. Rapid method for routine determination of caffeine and its metabolites by high-pressure liquid chromatography. Journal of Chromatography B 1994; 652: 104-108.
21. Evans DAP. N-acetyltransferase. Pharmacology and Therapeutics 1989; 42: 157-234.
22. Georga KA, Samanidou VF and Papadoyannis IN. Use of solid-phase extraction sorbent materials for high-performance liquid chromatography quantitation of caffeine metabolism products methylxanthines and methyluric acids in samples of biological origin. Journal of Chromatography B Biomedical Sciences and Applications 2001; 759: 209-218.
23. Grant DM, Tang BK and Kalow W. Variability in caffeine metabolism. Clinical Pharmacology and Therapeutics 1983; 33: 591-602.
24. Gu J, Liang D, Wang Y, Lu C and Wu X. Effects of N-acetyl transferase 1 and 2 polymorphisms on bladder cancer risk in Caucasians. Mutation Research 2005; 581: 97-104.
25. Gu L, Gonzales FJ, Kalow W and Tang BK. Biotranformation of caffeine, paraxanthine, theobromine and theophylline by c-DNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics 1992; 2: 73-77.
26. Guerciolini R, Szumlanski C and Weinshilboum RM. Human liver xanthine oxidase: Nature and extent of individual variation. Clinical Pharmacology and Therapeutics 1991; 50: 663-672.
27. Hein DW. N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene 2006; 25: 1649-1658.
28. Hong C, Tang B, Rao V, Agarwal S, Martin L, Tritchler D, Yaffe M and Boyd NF. Cytochrome P450 1A2 (CYP1A2) activity, mammographic density and oxidative stress: a cross-sectional study. Breast Cancer Research 2004; 6: 338-351.
29. Jetter A, Kinzig-Schippers M, Illauer M, Hermann R, Erb K, Borlak J, Wolf H, Smith G, Cascorbi I, Sorgel F and Fuhr U. Phenotyping of N-acetyltransferase type 2 by caffeine from uncontrolled dietary exposure. European Journal of Clinical Pharmacology 2004; 60: 17-21.
30. Jiang Z, Dragin N, Jorge-Nebert LF, Martin MV, Guengerich FP, Aklillu E, Ingelman-Sundberg M, Hammons GJ, Lyn-Cook BD, Kadlubar FF, Saldana SN, Sorter M, Vinks AA, Nassr N, von Richter O, Jin L and Nebert DW. Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype. Pharmacogenetics and Genomics 2006; 16: 359-367.
31. Kalow W and Tang BK. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clinical Pharmacology and Therapeutics 1991; 50: 508-519.
32. Kalow W and Tang BK. The use of caffeine for enzyme assays a critical appraisal. Clinical Pharmacology and Therapeutics 1993; 53: 503-514.
33. Kashuba AD, Bertino JS Jr, Kearns GL, Leeder JS. James AW and Gotschall R. Quantification of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2 and xanthine oxidase activity determined with caffeine phenotyping. Clinical Pharmacology and Therapeutics 1998; 63: 540-551.
34. Krul C and Hageman G. Analysis of urinary caffeine metabolites to assess biotransformation enzyme activities by reversed-phase high-performance liquid chromatography. Journal of Chromatography B Biomedical Sciences and Applications 1998; 709: 27-34.
35. Lelouet H, Bechtel YC, Paitaud G, Brientini MP, Miguet JP and Bechtel PR. Caffeine metabolism in a group of 67 patients with primary biliary cirrhosis. International Journal of Clinical Pharmacological and Therapeutics 2001; 39: 25-32.
36. Le Marchand L, Franke AA, Custer L, Wilkens LR and Cooney RV. Lifestyle and nutritional correlates of cytochrome CYP1A2 activity: inverse associations with plasma lutein and alpha-tocopherol. Pharmacogenetics 1997; 7: 11-19.
37. Lemoine A, Gautier JC, Azoulay D, Kiffel L, Belloc C, Guengerich FP, Maurel P, Beaune P and Leroux JP. Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P450 3A4 in human liver. Molecular Pharmacology 1993; 43: 827-832.
38. Li H, Cui H, Liu X and Zweier JL. Xanthine oxidase catalyzes anaerobic transformation of organic nitrates to nitric oxide and nitrosothiols: characterization of this mechanism and the link between organic nitrate and guanylyl cyclase activation. Journal of Biological Chemistry 2005; 280: 16594-16600.
39. Long JR, Egan KM, Dunning L, Shu XO, Cai Q, Cai H, Dai Q, Holtzman J, Gao YT and Zheng W. Population-based case-control study of AhR (aryl hydrocarbon receptor) and CYP1A2 polymorphisms and breast cancer risk. Pharmacogenetics and Genomics 2006; 16: 237-243.
40. Masubuchi Y, Hosokawa S, Horie T, Suzuki T, Ohmori S, Kitada M and Narimatsu S. Cytochrome. P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. Drug Metabolism and Disposition 1994; 22: 909-915.
41. Messina ES, Tyndale RF and Sellers EM. A major role for CYP2A6 in nicotine C-oxidation by human liver liver microsomes. Journal of Pharmacology and Experimental Therapeutics 1997; 282: 1608-1614.
42. Moonen H, Engels L, Kleinjans J and Kok T. The CYP1A2-164A→C polymorphism (CYP1A2*1F) is associated with the risk for colorectal adenomas in humans. Cancer Letters 2005; 229: 25-31.
43. Nowell S, Sweeney C, Hammons G, Kadlubar FF and Lang NP. CYP2A6 activity determined by caffeine phenotyping: association with colorectal cancer risk. Cancer Epidemiology, Biomarkers and Prevention 2002; 11: 377-383.
44. Nyeki A, Biollaz J, Kesserling UW and Decosterd LA. Extractionless method for the simultaneous high-performance liquid chromatographic determination of urinary caffeine metabolites for N-acetyltransferase 2, cytochrome P4501A2 and xanthine oxidase activity assessment. Journal of Chromatography B Biomedical Sciences and Applications 2001; 755: 73-84.
45. Oscarson M. Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: implications for interindividual differences in nicotine metabolism. Drug Metabolism and Disposition 2001; 29: 91-95.
46. Pontes ZB, Vincent-Viry M, Gueguen R, Galteau MM and Siest G. Acetylation phenotypes and biological variation in a French Caucasian population European Journal of Clinical Chemistry and Clinical Biochemistry 1993; 31: 59-68.
47. Rasmussen BB and Brosen K. Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase and N-acetyltransferase activity in humans. Therapeutic Drug Monitoring 1996; 18: 254-262.
48. Relling MV, Lin JS, Ayers GD and Evans WE. Racial and gender differences in N-acetyltrasferase, xanthine oxidase and CYP1A2 activities. Clinical Pharmacology and Therapeutics 1992; 52: 643-658.
49. Rostami-Hodjegan A, Nurminen S, Jackson PR and Tucker GT. Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Pharmacogenetics 1996; 6: 121-149.
50. Saruwatari J, Nakagawa K, Shindo J, Tajiri T, Fujieda M, Yamazaki H, Kamataki T and Ishizaki T. A population phenotyping study of three drug-metabolizing enzymes in Kyushu, Japan, with use of the caffeine test. Clinical Pharmacology and Therapeutics 2002; 72: 200-208.
51. Schneider H, Ma L and Glatt H. Extractionless method for the determination of urinary caffeine metabolites using high-performance liquid chromatography coupled with tandem mass spectrometry. Journal of Chromatography B: Analytical Technology in the Biomedical and Life Sciences 2003; 789: 227-237.
52. Schneider LS, Farlow MR, Henderson VW and Pogoda JM. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. Neurology 1996; 46: 1580-1584.
53. Tancheva-Poor I, Zaigler M, Rietbrock S and Fuhr U. Estimation of cytochrome P450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test. Pharmacogenetics 1999; 9: 131-144.
54. Tang BK, Kadar D, Qian L, Iriah J, Yip J and Kalow W. Caffeine as a metabolic probe: validation of its use for acetylator phenotyping. Clinical Pharmacology and Therapeutics 1991; 49: 648-657.
55. Thornton-Manning J, Appleton ML, Gonzalez FJ and Jost GS. Metabolism of 3-methylindole by vaccinia-expressed P450 enzymes: correlation of 3-methyleneindolenine formation and protein-binding. Journal of Pharmacology and Experimental Therapeutics 1996; 276: 21-29.
56. Vistisen K, Loft S and Poulsen HE. Cytochrome P450 IA2 activity in man measured by caffeine metabolism: effect of smoking, broccoli and exercise. Advances in Experimental Medicine and Biology 1991; 283: 407-411.
57. Wong P, Villeneuve G, Tessier V, Banerjee K, Nedev H, Jean-Claude BJ and Leyland-Jones B. Stability of 5-acetamido-6-formylamino-3-methyluracil in buffers and urine. Journal of Pharmaceutical and Biomedical Analysis 2002; 28: 693-700.
58. Yamazaki H, Shaw PM, Guengerich FP and Shimada T. Roles of cytochromes P450 1A2 and 3A4 in the oxidation of estradiol and estrone in human liver microsomes. Chemical Research in Toxicology 1998; 11: 659-665.